StockUS listing USMTVANASDAQHealthcareCapital Destroyer

MetaVia Inc.(MTVA) Stock Analysis | Healthcare

USD --+0.00%
Reward33Low
Risk58Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 8.56M
Reward Ratingⓘ33 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ58 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on MTVA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is MetaVia Inc.?

, a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.

AI Brief Pro

The brief on MetaVia Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is MetaVia Inc.?

, a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.56M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.242
Insider Activity
12M windowNo data
No insider activity data available for this ticker.